Stockscreener 앱 받기
12.40
1.70%
-0.215
시간 외 거래:
12.40
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
Can MiNK Therapeutics Inc. (6Q40) stock sustain breakout momentum2025 Geopolitical Influence & Reliable Price Action Trade Plans - ulpravda.ru
How MiNK Therapeutics Inc. (6Q40) stock behaves under inflation pressureJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - ulpravda.ru
How MiNK Therapeutics Inc. (6Q40) stock trades under stagflationTrade Risk Assessment & Daily Risk Controlled Trade Plans - ulpravda.ru
MiNK Therapeutics to begin phase 1 trial of iNKT cell therapy for GvHD - Investing.com Australia
MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease - The Manila Times
Trial tests cell therapy to prevent life-threatening transplant complication - Stock Titan
MiNK Therapeutics announces reverse stock split - MSN
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Will MiNK Therapeutics Inc. stock reach all time highs in 2025Currency Fluctuation Impact & Learn What Analysts Rate “Strong Buy” - ulpravda.ru
Price-Driven Insight from (INKT) for Rule-Based Strategy - Stock Traders Daily
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
MiNK Therapeutics announces board resignation amid public appointment - TipRanks
Treasury Yields: How MiNK Therapeutics Inc 6Q40 stock responds to job market shiftsDay Trade & Real-Time Volume Triggers - moha.gov.vn
Risk Report: Will MiNK Therapeutics Inc 6Q40 stock enhance shareholder valueWeekly Trade Review & Precise Trade Entry Recommendations - moha.gov.vn
The Technical Signals Behind (INKT) That Institutions Follow - Stock Traders Daily
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of “Hold” from Analysts - Defense World
MiNK Therapeutics, Inc. Financial Statements – GETTEX:6Q40 - TradingView — Track All Markets
Published on: 2025-12-21 01:45:03 - Улправда
Why MiNK Therapeutics Inc. stock attracts global investors2025 Market Trends & Short-Term High Return Ideas - Улправда
Signal Recap: Why MiNK Therapeutics Inc. (6Q40) stock could rally strongly2025 Geopolitical Influence & Safe Entry Zone Identification - moha.gov.vn
Wall Street Zen Downgrades MiNK Therapeutics (NASDAQ:INKT) to Sell - Defense World
Can MiNK Therapeutics Inc. stock deliver consistent earnings growth2025 AllTime Highs & Free Growth Oriented Trading Recommendations - Улправда
Published on: 2025-12-20 10:06:06 - Улправда
Total debt per share of MiNK Therapeutics, Inc. – MUN:6Q40 - TradingView — Track All Markets
Why MiNK Therapeutics Inc. stock is seen as undervaluedJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Is MiNK Therapeutics Inc. stock in correction or buying zone2025 Price Action Summary & Free High Return Stock Watch Alerts - Улправда
Will MiNK Therapeutics Inc. stock split again soonWeekly Investment Recap & Accurate Entry/Exit Alerts - DonanımHaber
Why MiNK Therapeutics Inc. (6Q40) stock could rally stronglyJuly 2025 Gainers & Real-Time Buy Signal Notifications - DonanımHaber
Published on: 2025-12-19 11:33:23 - Улправда
Published on: 2025-12-19 08:39:05 - Улправда
Trading Systems Reacting to (INKT) Volatility - Stock Traders Daily
Bond Watch: Is MiNK Therapeutics Inc. stock in correction or buying zoneJuly 2025 Update & Community Consensus Trade Signals - BỘ NỘI VỤ
Why MiNK Therapeutics Inc. stock is favored by top institutionsWeekly Trading Summary & Community Verified Trade Signals - Newser
How Mink Therapeutics Inc. (INKT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Is MiNK Therapeutics Inc. (6Q40) stock inflation resilientQuarterly Profit Report & Daily Growth Stock Tips - Newser
What downside risks could hit MiNK Therapeutics Inc. (6Q40) stockJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - Newser
MiNK Therapeutics (INKT) Stock Analysis Report | Financials & Insights - Benzinga
Why MiNK Therapeutics Inc. (6Q40) stock appeals to dividend investorsQuarterly Trade Summary & Growth Focused Entry Point Reports - Newser
MiNK Therapeutics (INKT) director awarded 1,263 RSUs for board service - Stock Titan
Will MiNK Therapeutics Inc. (6Q40) stock recover faster than industryStock Surge & Momentum Based Trading Signals - Newser
How MiNK Therapeutics Inc. (6Q40) stock compares with tech leaders2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - Newser
Published on: 2025-12-02 06:12:45 - Newser
Will MiNK Therapeutics Inc. (6Q40) stock outperform value peersMarket Activity Recap & Target Return Focused Stock Picks - Newser
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Aug Opening: Why MiNK Therapeutics Inc. stock attracts global investorsAnalyst Downgrade & AI Based Buy/Sell Signal Reports - moha.gov.vn
(INKT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MiNK Therapeutics Inc 6Q40 Stock Analysis and ForecastBull Market Opportunities & Learn From the Strategies of Institutions - earlytimes.in
MiNK Therapeutics Inc Stock Analysis and ForecastSupport Level Holds & Small Capital Trading Plans - earlytimes.in
MiNK Therapeutics announces publication of new preclinical data for MiNK-215 - MSN
How reliable is MiNK Therapeutics Inc. (6Q40) stock dividend growthEarnings Summary Report & Free Safe Capital Growth Stock Tips - newser.com
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors - The Manila Times
0.80%
4.56%
자본화:
|
볼륨(24시간):